Business Wire

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion


Kindeva Drug Delivery(Kindeva),a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.

This press release features multimedia. View the full release here:

This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice. This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

The converted pMDI products will be available for licensing with anticipated launches occurring in-line with the expected commencement of a phase-down of existing pMDI systems containing HFC-134a and HFC-227ea within the European Union.

Orbia Fluorinated Solutions Business (Koura) President Gregg Smith said, “This is a significant step forward in bringing our lower GWP medical propellant Zephex 152a to the market and we are excited to partner with Kindeva to ensure patients have access to this life saving technology.”

David Stevens, Global Chief Commercial Officer of Kindeva said, “We are proud to partner with Koura to help achieve the dual objectives of significantly reducing the environmental impact of pMDI inhalers and ensuring patient access to inhaler options is not compromised.”

Stevens continued, “Kindeva has a rich history of innovation in the pMDI market and our comprehensive development and manufacturing capabilities uniquely enable us to help lead this transition. This strategic collaboration is symbolic of not only the commitment both partners have for advancing sustainability and advocating for patient choice, but also of the shared values of the two organizations.”

Koura and Kindeva are both exhibiting at the Drug Delivery to the Lungs conference (DDL) in Edinburgh, U.K., December 6-8 (booth #146 and #147, respectively) where they will be speaking with industry leaders on the low GWP propellent, 152a, and further relevant topics.

About Kindeva Drug Delivery

Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary and nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit

About Orbia

Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) is a company driven by a shared purpose: to advance life around the world. Orbia operates in the Polymer Solutions (Vestolit and Alphagary), Building and Infrastructure (Wavin), Precision Agriculture (Netafim), Connectivity Solutions (Dura-Line) and Fluorinated Solutions (Koura) sectors. The five Orbia businesses have a collective focus on expanding access to health and well-being, reinventing the future of cities and homes, ensuring food, water and sanitation security, connecting communities to information and enabling the energy transition with basic and advanced materials, specialty products and innovative solutions. Orbia has a global team of over 24,000 employees, commercial activities in more than 100 countries and operations in over 50, with global headquarters in Boston, Mexico City, Amsterdam and Tel Aviv. The company generated $9.6 billion in revenue and $1.95 billion of EBITDA in 2022. To learn more, visit:

AboutOrbia Fluorinated Solutions (Koura)

Orbia Fluorinated Solutions business, Koura, is a global leader in the development, manufacture and supply of fluoroproducts that play a fundamental role in enhancing everyday lives and shortening the path to a sustainable, circular economy. Backed by over 35 years of experience, Orbia Fluorinated Solutions (Koura) products are used in a vast range of applications including electric vehicles and energy storage, urban and rural infrastructure, indoor climate management, food and medicine refrigeration and even in treating respiratory conditions through the development of healthy and innovative low-GWP propellants for metered-dose inhalers. Orbia Fluorinated Solutions (Koura) has 1,600 employees and 13 manufacturing facilities worldwide, serving 60 countries through a global sales and distribution network.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Kindeva Drug Delivery
Lindsey Langemeier
+1 402-405-4269

Orbia Fluorinated Solutions (Koura)
Valeria Barragan Villanueva
Director, Product Management, Orbia Fluorinated Solutions (Koura)
+44 7873 626557

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Empowers Clients and Partners with the Launch of Global Media Division29.2.2024 14:00:00 CET | Press release

NIQ, the world’s leading consumer intelligence company, is pleased to announce the launch of its new Media Division, a strategic initiative designed to enhance the value advertisers derive from their marketing efforts and enable partners in support of our advertiser clients. This move underscores NIQ’s continued commitment to providing clients with the Full View™ and strengthening their marketing capabilities. Heading the Global Media Division is Lana Busignani, a seasoned professional with an impressive track record in driving strategy across various media products. Formerly with Quotient Technology Inc., Lana brings her extensive experience to lead this strategic initiative, drawing from seven years at Nielsen Media, initially leading global Marketing Effectiveness and then serving as general manager of international media services. With a wealth of market research experience, including 15 years at IPSOS leading global advertising intelligence, Lana is well-positioned to drive the su

FourKites Premier Carriers Deliver Outsized Growth in Second Half of 202329.2.2024 13:30:00 CET | Press release

Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), recognising the growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport. Carriers featured on FourKites’ PCL deliver high-quality and consistent shipment data, facilitating faster turnaround times and optimised performance for shippers and carriers alike. FourKites’ latest data reaffirms the importance of providing market-leading shipment visibility to customers, highlighting outsized growth amongst members of the Premier Carrier List. For instance, FourKites’ data indicates that new carriers who qualified for the PCL in H2 2023 saw an 11% month-over-month increase in shipment volume in the second half of 2023 compared to the overall network average. Further, the data shows that carriers on the PCL have approximately 4.5 times more shipper customers than non-PCL carr

Aiosyn Launches Kidney Image Analysis Services Through Its NephroPath Platform to Accelerate Drug Development Studies29.2.2024 13:26:00 CET | Press release

Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services. This press release features multimedia. View the full release here: Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored). (Photo: Business Wire) The NephroPath platform provides computational pathology algorithms for a detailed evaluat

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases29.2.2024 13:00:00 CET | Press release

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors and a team of industry veterans, including scientific co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower, who see the promise in Kenai’s approach to treating central nervous system disorders,” said Nick Manusos, chief executive officer of Kenai Therapeutics. “Their guidance will be invaluable as we soon advance our lead candidate, RNDP-001, into the clinic for the treatment of Parkinson’s disease.” RNDP-001 is an iPSC-derived

Suzano Invests R$18.6 Billion in 202329.2.2024 11:42:00 CET | Press release

Suzano, the world’s largest pulp producer, announces its financial statements for the full fiscal year of 2023. Total investment of R$18.6 billion in 2023, a 14% increase on FY22 FY23 Net revenues of R$39.8 billion, a 20% decrease on FY22 FY23 Adjusted EBITDA of R$18.3 billion, a 35% decrease on FY22 FY23 Operating cash generation of R$11.6 billion, a 49% decrease on FY22 FY23 Pulp sales totalled 10.2 million tons, a 4% decrease on FY22 FY23 Paper sales totalled 1.3 million tons, a 1% decrease on FY22 Despite the marked decline in global pulp prices over the course of 2023, Suzano has invested over R$18bn to guarantee its future success. It is currently finalising the construction of the Cerrado Project, the world’s largest single-line pulp mill, and has expanded its forestry estate, safeguarding supply and enhancing future competitiveness. Walter Schalka, CEO of Suzano, said: “Our investment cycle, including the highest annual investment ever, in 2023, represents the largest in our ce

HiddenA line styled icon from Orion Icon Library.Eye